Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226485 | 1.00 | CYP2D6 (0.48) | CYP2D6CYP2C9CYP2C19RECQLTSHR | |
| SCHEMBL666474 | 0.90 | GRM8 (0.49) | CYP2D6CYP2C9CYP2C19RECQLTSHR | |
| SCHEMBL27331108 | 0.83 | ALDH1A1 (0.47) | CYP2D6CYP2C9CYP2C19TSHRLMNA | |
| SCHEMBL16809247 | 0.83 | TSHR (0.52) | TSHRLMNAL3MBTL1MEN1HPGD | |
| SCHEMBL1935768 | 0.82 | L3MBTL1 (0.60) | CYP2D6CYP2C9CYP2C19RECQLTSHR | |
| SCHEMBL4703596 | 0.81 | TSHR (0.53) | TSHRLMNAL3MBTL1MEN1HPGD | |
| SCHEMBL28862613 | 0.81 | SCN4A (0.35) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL8297473 | 0.80 | MEN1 (0.51) | LMNAL3MBTL1MEN1HPGDKMT2A | |
| SCHEMBL31163362 | 0.80 | MEN1 (0.51) | LMNAL3MBTL1MEN1HPGDKMT2A | |
| SCHEMBL665345 | 0.80 | MEN1 (0.51) | LMNAL3MBTL1MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-8637532-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | CYP2D6 2038/4885CYP2C9 3470/4885CYP2C19 2659/4885 |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | CYP2D6 2038/4885CYP2C9 3470/4885CYP2C19 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.